Delta Air Lines Inc. (DE) (DAL) Falls 5.2% for February 05

Equities Staff  |

One of the S&P 500’s big losers for Friday February 05 was Delta Air Lines Inc. (DE) (DAL). The company’s stock fell 5.2% to $41.75 on volume of 10.07 million shares.

The stock opened the day at 44.14 and traded between a low of $41.68 and a high of $44.55. The stock finished the day down $2.29 per share. Delta Air Lines Inc. (DE) has an average daily volume of 9.66 million and a total float of 786.47 million shares. The 50-day SMA for Delta Air Lines Inc. (DE) is $48.09 and its 200-day SMA is $46.04. The high for the stock over the last 52 weeks is $52.77 and the low is $34.61.

Delta Air Lines Inc provides scheduled air transportation for passengers and cargo throughout the United States and around the world. The Company's business segments are airline and refinery.

Delta Air Lines Inc. (DE) is centered in Atlanta, GA, and has 83,000 employees. Today’s trading day leaves the company with a market cap of $32.84 billion. The company has a P/S ratio of n/a, P/B ratio of 3.18, and a 8.3.

For a complete fundamental analysis analysis of Delta Air Lines Inc. (DE), check out’s Stock Valuation Analysis report for DAL. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 2

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 2 of this 2 part interview at the World Economic Forum at Davos 2019

Emerging Growth

Q BioMed Inc

Q BioMed Inc is a biomedical acceleration and development company. The company is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences…